Stockscreener 앱 받기
1.635
9.67%
-0.175
전일 마감가:
$1.81
열려 있는:
$1.81
하루 거래량:
364.34K
Relative Volume:
0.53
시가총액:
$181.53M
수익:
$21.05M
순이익/손실:
$-142.93M
주가수익비율:
-1.1767
EPS:
-1.3895
순현금흐름:
$-184.07M
1주 성능:
-24.31%
1개월 성능:
-36.38%
6개월 성능:
+34.02%
1년 성능:
+15.96%
1일 변동 폭
$1.625
$1.84
1주일 범위
$1.625
$2.16
52주 변동 폭
$1.09
$3.3999
알렉터 Stock (ALEC) Company Profile
명칭
Alector Inc
전화
415-231-5660
주소
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.635 | 200.96M | 21.05M | -142.93M | -184.07M | -1.3895 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
알렉터 Stock (ALEC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2026-03-10 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-10-22 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-22 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-10-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-10-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-07-28 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-17 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-29 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-26 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-14 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-09-25 | 개시 | Goldman | Sell |
| 2023-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-13 | 개시 | Goldman | Sell |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-27 | 개시 | William Blair | Outperform |
| 2021-01-15 | 재개 | BofA Securities | Buy |
| 2020-06-24 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-19 | 개시 | Stifel | Buy |
| 2019-11-21 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | Barclays | Overweight |
| 2019-03-04 | 개시 | BofA/Merrill | Buy |
| 2019-03-04 | 개시 | Morgan Stanley | Overweight |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
모두보기
알렉터 주식(ALEC)의 최신 뉴스
[Form 4] Alector, Inc. Insider Trading Activity - Stock Titan
Alector (ALEC) CEO sells shares to cover RSU tax obligations - Stock Titan
Alector (ALEC) CFO Berkley sells shares to cover RSU tax obligations - Stock Titan
ALEC (NASDAQ: ALEC) Form 144 lists 3,475 restricted common shares - Stock Titan
Alector (NASDAQ: ALEC) Rule 144 notice lists RSU vesting and stock sales - Stock Titan
Alector (NASDAQ: ALEC) files to sell 132,805 RSU shares after vesting - Stock Titan
Alector halts mid-stage trial for Alzheimer’s candidate developed with GSK - MSN
ALEC Q1 2026 Earnings: Narrower Loss Surprises as Pipeline Progress Highlights Biotech ResilienceGuidance vs Actual - newsline.com
ALEC Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative Pipeline - The Legal Advocate
Alector Shares Up, Focus Turns to Pipeline After Setback - Bez Kabli
ALEC Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises, No Revenue YetQuarterly Earnings - thelegaladvocate.com
Alector Inc. (ALEC) Holds Steady at $2.21 as Key Support and Resistance Levels Come into FocusOrder Block - The Legal Advocate
Number of shareholders of Alector, Inc. – DUS:0Z2 - TradingView
Alector Inc. (ALEC) Shows Resilience: Shares Up 4.25% as Biotech Sector Watches Key LevelsCalendar Spread Trade - The Legal Advocate
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus - Yahoo Finance
Alector (ALEC) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.21High Attention Stocks - Newser
Should You Sell Alector (ALEC) After -2.83% Drop? 2026-05-15Beta Neutral Pair - newsline.com
Polaris entities hold 4.85M ALEC shares (ALEC) — Amendment No.7 - Stock Titan
MSN - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alector (ALEC), Spyre Therapeutics (SYRE) and Perspective Therapeutics (CATX) - The Globe and Mail
TradingKey - TradingKey
Alector Establishes $125 Million At-the-Market Offering - The Globe and Mail
Myles Minter Reiterates Hold on Alector as Late-Stage Trial Failures Trigger Pipeline Reset but Next-Gen Brain Carrier Platform Offers Long-Term Optionality - TipRanks
Alector (ALEC) Reports Q1 Revenue Shortfall Amidst Strategic Dev - GuruFocus
Alector, Inc. Announces $125 Million Common Stock Sales Agreement with TD Securities (USA) LLC - Minichart
Alector: Q1 Earnings Snapshot - theheraldreview.com
Alector posts first quarter 2026 financial results amid new business updates - Traders Union
Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Alector (NASDAQ: ALEC) establishes $125M stock ATM facility - Stock Titan
Alector (NASDAQ: ALEC) files $125M ATM offering with TD Cowen - Stock Titan
Alector (NASDAQ: ALEC) narrows Q1 2026 loss as it refocuses pipeline - Stock Titan
Alector Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Alector | 10-Q: Q1 2026 Earnings Report - Moomoo
Alector | 8-K: Alector Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus - Stock Titan
BRIEF-Alector Q1 Basic EPS USD -0.21 - TradingView
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
MSN Money - MSN
Transcript : Alector, Inc.Special Call - marketscreener.com
Alector Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Morgan Stanley Maintains Alector(ALEC.US) With Sell Rating, Raises Target Price to $2 - Moomoo
Five-Way Obesity Drug Shows Effectiveness in Mice; Alector Stops Alzheimer’s Trial - geneonline.com
Franklin Lexington Private Markets Fund's Alector Inc(ALEC) Holding History - GuruFocus
Morgan Stanley raises Alector stock price target on pipeline focus By Investing.com - Investing.com Australia
Morgan Stanley raises Alector stock price target on pipeline focus - Investing.com
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Alector (ALEC) - The Globe and Mail
Failure of GSK-partnered Alzheimer’s drug a fresh setback for Alector - The Pharma Letter
알렉터 (ALEC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알렉터 주식 (ALEC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wong-Sarad Grace | Principal Accounting Officer |
Jun 02 '26 |
Sale |
1.97 |
5,709 |
11,271 |
98,936 |
| Wong-Sarad Grace | Principal Accounting Officer |
Jun 03 '26 |
Sale |
1.88 |
3,475 |
6,543 |
95,461 |
| Berkley Neil Lindsay | CFO & Chief Business Officer |
Jun 02 '26 |
Sale |
1.97 |
19,360 |
38,221 |
379,900 |
1.13%
3.22%
자본화:
|
볼륨(24시간):